{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:16:29Z","timestamp":1783638989008,"version":"3.55.0"},"reference-count":47,"publisher":"Georg Thieme Verlag KG","issue":"CP","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"University Medical Centre Ljubljana","award":["20240051, 20250023"],"award-info":[{"award-number":["20240051, 20250023"]}]},{"name":"Amgen"},{"name":"Sanofi"},{"DOI":"10.13039\/501100005788","name":"Medizinische Universit\u00e4t Wien","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"crossref","award":["Programs P3-0308 and P1-0170, P1-0420"],"award-info":[{"award-number":["Programs P3-0308 and P1-0170, P1-0420"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Endothelial dysfunction is an independent predictor of cardiovascular events in patients with established atherosclerosis, while the circulating levels of endothelial progenitor cells (EPCs) reflect active endothelial function in heart failure patients. Although protein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors (PCSK9i) lower lipid concentration and reduce cardiovascular events, their impact on endothelial function remains poorly understood.<\/jats:p>\n                  <jats:p>Purpose We aimed to examine the effect of PCSK9i on the levels of EPCs in the peripheral blood of patients with chronic coronary disease and significantly elevated lipoprotein(a) (Lp(a)) concentrations.<\/jats:p>\n                  <jats:p>Methods In this randomized, double-blind, placebo-controlled trial, we included 100 statin-treated patients at least 6 months post-myocardial infarction with elevated Lp(a) values. The patients received PCSK9i or a placebo every 2 weeks for 6 months. Biochemical and flow cytometric analyses of peripheral blood mononuclear cells were performed at baseline and after 6 months.<\/jats:p>\n                  <jats:p>Results Treatment with PCSK9i increased the levels of mature EPCs (CD34+) compared with placebo (p = 0.003). In contrast, no significant effects were observed on early EPC subtypes (CD34+CD309+, CD34+CD133+, CD133+CD309+, and CD133+; p = 0.611, p = 0.451, p = 0.739, and p = 0.161, respectively). The increase in mature EPCs (CD34+) levels did not correlate with changes in PCSK9 concentration. No associations were detected between changes in PCSK9 concentration and changes in levels of EPC subtypes predominantly expressing CD309, nor between changes in levels of any EPCs and lipoprotein concentration variations at baseline or at the end of the study.<\/jats:p>\n                  <jats:p>Conclusion In patients with chronic coronary disease, treatment with PCSK9i increases circulating levels of mature CD34+ EPCs, without affecting other EPC subtypes.<\/jats:p>","DOI":"10.1055\/a-2901-2564","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T22:56:31Z","timestamp":1782341791000},"source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["PCSK9 Inhibitors Increase CD34+ But Not Other Endothelial Progenitor Cells in Patients with Chronic Coronary Disease and Increased Lp(a) Values"],"prefix":"10.1055","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct04613167","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-4781","authenticated-orcid":false,"given":"Sabina","family":"Ugov\u0161ek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja","family":"Rehberger Likozar","sequence":"additional","affiliation":[{"name":"University Medical Centre Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"],"department":["Department of Vascular Diseases"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Levstek","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"],"department":["Laboratory for Translational Medical Biochemistry"]},{"name":"Clinical Institute for Special Laboratory Diagnostics, University Children\u2019s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Trebu\u0161ak Podkraj\u0161ek","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"],"department":["Laboratory for Translational Medical Biochemistry"]},{"name":"Clinical Institute for Special Laboratory Diagnostics, University Children\u2019s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja","family":"Zupan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frieda","family":"Marka","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria","place":["Vienna"],"department":["Department of Internal Medicine II"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Trimmel","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria","place":["Vienna"],"department":["Department of Internal Medicine II"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Brekalo","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria","place":["Vienna"],"department":["Department of Internal Medicine II"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter S.","family":"Speidl","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria","place":["Vienna"],"department":["Department of Internal Medicine II"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp J.","family":"Hohensinner","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Cluster for Cardiovascular Research, Vienna, Austria","place":["Vienna"]},{"name":"Cardiovascular Institute, Medical University of Vienna, Vienna, Austria","place":["Vienna"],"department":["Center for Biomedical Research and Translational Surgery"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6874-5349","authenticated-orcid":false,"given":"Patrick","family":"Haider","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria","place":["Vienna"],"department":["Department of Internal Medicine II"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miran","family":"\u0160ebe\u0161tjen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"]},{"name":"University Medical Centre Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"],"department":["Department of Vascular Diseases"]},{"name":"Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"],"department":["Laboratory for Translational Medical Biochemistry"]},{"name":"University Medical Centre Ljubljana, Ljubljana, Slovenia","place":["Ljubljana"],"department":["Department of Cardiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736 (20)32226-1","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","journal-title":"Lancet"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"e000426","DOI":"10.1161\/JAHA.113.000426","article-title":"Peripheral endothelial function and cardiovascular events in high-risk patients","volume":"2","author":"Y Matsuzawa","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"08","key":"ref3","first-page":"281","article-title":"TNF-\u03b1 predicts endothelial function and number of CD34+ cells after stimulation with G-CSF in patients with advanced heart failure","volume":"9","author":"S Ugov\u0161ek","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"issue":"21","key":"ref4","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehq184","article-title":"Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis","volume":"31","author":"E I Lev","year":"2010","journal-title":"Eur Heart J"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/CIRCULATIONAHA.117.029870","article-title":"Acute coronary syndromes: the way forward from mechanisms to precision treatment","volume":"136","author":"F Crea","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"N Werner","year":"2005","journal-title":"N Engl J Med"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/157016111794519345","article-title":"The pleiotropic effects of ARB in vascular endothelial progenitor cells","volume":"9","author":"K Matsuura","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"issue":"23","key":"ref8","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2174\/138161210792062939","article-title":"Smoking and endothelial progenitor cells: a revision of literature","volume":"16","author":"R Di Stefano","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1161\/01.ATV.0000243941.72375.15","article-title":"Increased ratio of CD31+\/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia","volume":"26","author":"M Pirro","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1194\/jlr.M500507-JLR200","article-title":"Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase","volume":"47","author":"F X Ma","year":"2006","journal-title":"J Lipid Res"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/sctm.16-0360","article-title":"Endothelial progenitors: a consensus statement on nomenclature","volume":"6","author":"R J Medina","year":"2017","journal-title":"Stem Cells Transl Med"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.RES.0000137877.89448.78","article-title":"Endothelial progenitor cells: characterization and role in vascular biology","volume":"95","author":"C Urbich","year":"2004","journal-title":"Circ Res"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/biom12010026","article-title":"Lipoprotein (a)-the crossroads of atherosclerosis, atherothrombosis and inflammation","volume":"12","author":"S Ugov\u0161ek","year":"2021","journal-title":"Biomolecules"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/mmr.2024.13347","article-title":"Downregulation of microRNA-221-3p promotes angiogenesis of lipoprotein (a)-injured endothelial progenitor cells by targeting silent information regulator 1 to activate the RAF\/MEK\/ERK signaling pathway","volume":"30","author":"X Zhang","year":"2024","journal-title":"Mol Med Rep"},{"issue":"16","key":"ref15","doi-asserted-by":"crossref","first-page":"e019270","DOI":"10.1161\/JAHA.120.019270","article-title":"Characteristics and outcomes of early recurrent myocardial infarction after acute myocardial infarction","volume":"10","author":"R Nair","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"ref16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"M S Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"ref17","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"G G Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"176232","DOI":"10.1016\/j.ejphar.2023.176232","article-title":"Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients","volume":"963","author":"A Rehberger Likozar","year":"2024","journal-title":"Eur J Pharmacol"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3390\/ijms23031881","article-title":"Quantitative and functional assessment of the influence of routinely used cryopreservation media on mononuclear leukocytes for medical research","volume":"23","author":"P Haider","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"W T Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","article-title":"Statistical power analyses using G*power 3.1: tests for correlation and regression analyses","volume":"41","author":"F Faul","year":"2009","journal-title":"Behav Res Methods"},{"issue":"36","key":"ref22","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehaf079","article-title":"ESC scientific document group. 2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"C Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"01","key":"ref23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz826","article-title":"ESC scientific document group. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"F Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10557-020-07119-1","article-title":"The effect of proprotein convertase subtilisin kexin type 9 inhibitors on circulating endothelial progenitor cells in patients with cardiovascular disease","volume":"36","author":"O Itzhaki Ben Zadok","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"100896","DOI":"10.1016\/j.ajpc.2024.100896","article-title":"Circulating endothelial progenitor cells in patients with established cardiovascular disease treated with PCSK9 monoclonal antibodies","volume":"20","author":"C Gurevitz","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"24","key":"ref26","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1161\/hc2401.092816","article-title":"Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease","volume":"103","author":"M Vasa","year":"2001","journal-title":"Circulation"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V95.3.952.003k27_952_958","article-title":"Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors","volume":"95","author":"M Peichev","year":"2000","journal-title":"Blood"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2006-08-043471","article-title":"Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem\/progenitor cell principals","volume":"109","author":"M C Yoder","year":"2007","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2016.06.047","article-title":"Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34 (+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia","volume":"251","author":"V G Chantzichristos","year":"2016","journal-title":"Atherosclerosis"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10517-017-3753-7","article-title":"Effect of atorvastatin therapy on the level of CD34+CD133+CD309+ endothelial progenitor cells in patients with coronary heart disease","volume":"163","author":"A A Ansheles","year":"2017","journal-title":"Bull Exp Biol Med"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248413489771","article-title":"Increasing doses of simvastatin versus combined ezetimibe\/simvastatin: effect on circulating endothelial progenitor cells","volume":"18","author":"A E Pesaro","year":"2013","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMoa022287","article-title":"Circulating endothelial progenitor cells, vascular function, and cardiovascular risk","volume":"348","author":"J M Hill","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"ref33","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/01.CIR.0000124476.32871.E3","article-title":"Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease","volume":"109","author":"C Heeschen","year":"2004","journal-title":"Circulation"},{"issue":"09","key":"ref34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00228-011-1029-0","article-title":"Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients","volume":"67","author":"F Cacciatore","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.atherosclerosis.2009.12.005","article-title":"Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study","volume":"210","author":"F Pelliccia","year":"2010","journal-title":"Atherosclerosis"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2012.05.086","article-title":"Inhibition of Lp (a)-induced functional impairment of endothelial cells and endothelial progenitor cells by hepatocyte growth factor","volume":"423","author":"M Iwabayashi","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Z Ding","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1194\/jlr.M600020-JLR200","article-title":"Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine","volume":"47","author":"J M Brusq","year":"2006","journal-title":"J Lipid Res"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1038\/s41598-021-88941-x","article-title":"Endogenous PCSK9 may influence circulating CD45neg\/CD34bright and CD45neg\/CD34bright\/CD146neg cells in patients with type 2 diabetes mellitus","volume":"11","author":"R Tripaldi","year":"2021","journal-title":"Sci Rep"},{"issue":"05","key":"ref40","doi-asserted-by":"publisher","first-page":"e003497","DOI":"10.1161\/JAHA.116.002090","article-title":"Plasma levels of proprotein convertase Subtilisin\/Kexin type 9 are elevated in patients with peripheral artery disease and associated with metabolic disorders and dysfunction in circulating progenitor cells","volume":"5","author":"T H Chao","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1172\/JCI200113152","article-title":"HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase\/Akt pathway","volume":"108","author":"S Dimmeler","year":"2001","journal-title":"J Clin Invest"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"178777","DOI":"10.1016\/j.ejphar.2026.178777","article-title":"Evolocumab alleviates atherogenesis by inhibiting inflammation-mediated endothelial cell activation via the PI3K\/AKT\/NF-\u03baB pathway","volume":"1020","author":"C Peng","year":"2026","journal-title":"Eur J Pharmacol"},{"issue":"07","key":"ref43","first-page":"1715","article-title":"Effects of lipid lowering therapy optimization by PCSK9 inhibitors on circulating CD34+ cells and pulse wave velocity in familial hypercholesterolemia subjects without atherosclerotic cardiovascular disease: real-world data from two lipid units","volume":"10","author":"R Scicali","year":"2022","journal-title":"Biomedicine"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40256-020-00394-1","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of alirocumab in healthy Chinese subjects: a randomized, double-blind, placebo-controlled, ascending single-dose study","volume":"20","author":"H Li","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"e003323","DOI":"10.1161\/JAHA.116.003323","article-title":"Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies","volume":"5","author":"J Rey","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"American Heart Association Council on arteriosclerosis, thrombosis and vascular biology; council on cardiovascular radiology and intervention; and council on peripheral vascular disease. Lipoprotein (a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"G Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijcard.2020.05.008","article-title":"Short-term regulation of hematopoiesis by lipoprotein (a) results in the production of pro-inflammatory monocytes","volume":"315","author":"J G Schnitzler","year":"2020","journal-title":"Int J Cardiol"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2901-2564.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:47:04Z","timestamp":1783637224000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2901-2564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":47,"journal-issue":{"issue":"CP","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026]]}},"alternative-id":["a29012564"],"URL":"https:\/\/doi.org\/10.1055\/a-2901-2564","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,24]]},"published":{"date-parts":[[2026,6,24]]}}}